Journal Articles Conference Presentations Book Chapters Public Presentations

Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.

Griesenbach U, Alton EW

F1000Prime Reports

F1000Prime Rep. 2015; 7: 64.

 Download the Manuscript

Contact us about this publication

Print this page

Cystic fibrosis is the most common autosomal recessive genetic disease in Caucasians and has been extensively studied for many decades.

The cystic fibrosis transmembrane conductance regulator gene was identified in 1989.

It encodes a complex protein which has numerous cellular functions. Our understanding of cystic fibrosis pathophysiology and genetics is constantly expanding and being refined, leading to improved management of the disease and increased life expectancy in affected individuals.

Go Back to Publications     View on Pubmed (26097737)    View on Google Scholar


 

Other Publications by these authors
Lung clearance index in primary ciliary dyskinesia and bronchiectasis.
Irving SJ et al. American Journal Of Respiratory And Critical Care Medicine (2014) Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Alton EW et al. Gene Therapy (2013) The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
Alton EW et al. Biomaterials (2013) Self-reactive CFTR T cells in humans: implications for gene therapy.
Calcedo R et al. Human Gene Therapy. Clinical Development (2013) A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Alton EW et al. Thorax (2013) Expert opinion in biological therapy: update on developments in lung gene transfer.
Griesenbach U et al. Expert Opinion On Biological Therapy (2013)